New combo therapy aims to cut chemo and boost survival in leukemia

NCT ID NCT06481241

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding CAR-T cells to standard chemotherapy can help adults newly diagnosed with a certain type of leukemia (Ph-negative B-ALL) achieve deeper remission and need fewer chemo cycles. About 77 participants will receive CAR-T cells after initial chemo. The goal is to improve survival and quality of life while reducing side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR-T cells and venetoclax
What this could lead to: If successful, this could reduce the amount of chemotherapy needed and improve survival and quality of life for adults with a type of leukemia.
What could go wrong: This is an early-phase study with no control group, so results may not be definitive. CAR-T therapy carries risks like severe immune reactions and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT PHILADELPHIA CHROMOSOME NEGATIVE ALL

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hospital
RECRUITING

Tianjin, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.